Elemer Piros
Stock Analyst at Rodman & Renshaw
(3.11)
# 1,230
Out of 4,714 analysts
109
Total ratings
36.89%
Success rate
3.43%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FBLG FibroBiologics | Initiates: Buy | $12 | $2.12 | +466.04% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $2.08 | +717.31% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.95 | +464.10% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $22.98 | +117.58% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.26 | +1,249.21% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.57 | +3,739.44% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $2.89 | +3,602.42% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $0.76 | +1,754.30% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $5.39 | +1,143.04% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $43 | $4.61 | +832.75% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.11 | +194.60% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $0.78 | +867.74% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.77 | +747.46% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $7.18 | +192.48% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $4.45 | +753.93% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $3.12 | +1,182.05% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.78 | +541.77% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $10.10 | +1,028.71% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $5.34 | +3,645.32% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.76 | +511.70% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $9.03 | +265.45% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $33.46 | +19.55% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $40 | $1.28 | +3,025.00% | 3 | Jan 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.50 | +2,366.67% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $5.56 | +475.54% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $17.94 | +329.21% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.87 | +7,945.98% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.04 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $19.79 | +152.65% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $5.45 | +505.50% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $12.94 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $11.21 | +131.94% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $158.33 | -82.32% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $6.02 | +14,019.60% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $8.76 | +139.73% | 2 | Jul 12, 2017 |
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $2.12
Upside: +466.04%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $2.08
Upside: +717.31%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.95
Upside: +464.10%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $22.98
Upside: +117.58%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.26
Upside: +1,249.21%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.57
Upside: +3,739.44%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $2.89
Upside: +3,602.42%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $0.76
Upside: +1,754.30%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $5.39
Upside: +1,143.04%
Alto Neuroscience
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $4.61
Upside: +832.75%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.11
Upside: +194.60%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $0.78
Upside: +867.74%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $1.77
Upside: +747.46%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $7.18
Upside: +192.48%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $4.45
Upside: +753.93%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $3.12
Upside: +1,182.05%
Jun 30, 2023
Reiterates: Buy
Price Target: $5
Current: $0.78
Upside: +541.77%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $10.10
Upside: +1,028.71%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $5.34
Upside: +3,645.32%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.76
Upside: +511.70%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $9.03
Upside: +265.45%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $33.46
Upside: +19.55%
Jan 4, 2022
Upgrades: Buy
Price Target: $40
Current: $1.28
Upside: +3,025.00%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.50
Upside: +2,366.67%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $5.56
Upside: +475.54%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $17.94
Upside: +329.21%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $0.87
Upside: +7,945.98%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $13.04
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $19.79
Upside: +152.65%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $5.45
Upside: +505.50%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $12.94
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $11.21
Upside: +131.94%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $158.33
Upside: -82.32%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $6.02
Upside: +14,019.60%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $8.76
Upside: +139.73%